What is SIGMOVIR Biosystems?
SIGMOVIR Biosystems, Inc. is a Maryland-based biotechnology firm recognized for its expertise in utilizing the cotton rat model for the study of human infectious diseases. The company provides essential contract research services to academic and commercial entities, focusing on the efficacy testing of novel vaccines and therapeutics. The cotton rat model is a key differentiator, offering a more reliable alternative to traditional small animal models in preclinical research. SBI's team brings over a century of combined experience, contributing to numerous peer-reviewed publications and the development of critical cotton rat reagents, thereby solidifying its role in advancing biomedical research.
How much funding has SIGMOVIR Biosystems raised?
SIGMOVIR Biosystems has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for SIGMOVIR Biosystems?
The substantial late-stage funding positions SIGMOVIR Biosystems for accelerated growth and expanded service offerings. This strategic capital infusion is expected to fuel further development of their proprietary cotton rat model research capabilities and potentially broaden their client base. The company is poised to enhance its contribution to infectious disease research, supporting the development of next-generation vaccines and therapeutics through its specialized contract research services.
See full SIGMOVIR Biosystems company page
